These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 28294430)

  • 1. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.
    Leonardi CL; Blauvelt A; Sofen HL; Gooderham M; Augustin M; Burge R; Zhu B; Reich K
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1483-1490. PubMed ID: 28294430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
    Kimball AB; Luger T; Gottlieb A; Puig L; Kaufmann R; Burge R; Lin CY; Yosipovitch G
    Acta Derm Venereol; 2018 Jan; 98(1):98-102. PubMed ID: 28929168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
    Guenther L; Warren RB; Cather JC; Sofen H; Poulin Y; Lebwohl M; Terui T; Potts Bleakman A; Zhu B; Burge R; Reich K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1867-1875. PubMed ID: 28573743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
    Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
    Blauvelt A; Papp KA; Sofen H; Augustin M; Yosipovitch G; Katoh N; Mrowietz U; Ohtsuki M; Poulin Y; Shrom D; Burge R; See K; Mallbris L; Gordon KB
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1004-1013. PubMed ID: 28190255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
    Kimball AB; Luger T; Gottlieb A; Puig L; Kaufmann R; Nikaï E; Zhu B; Edson-Heredia E; Carlier H; Lin CY; Goldblum O; Yosipovitch G
    J Am Acad Dermatol; 2016 Dec; 75(6):1156-1161. PubMed ID: 27692498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
    Paul C; Guenther L; Torii H; Sofen H; Burge R; Lin CY; Potts Bleakman A; Mallbris L; Poulin Y
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):68-72. PubMed ID: 28881462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.
    Kavanaugh A; Marzo-Ortega H; Vender R; Wei CC; Birt J; Adams DH; Benichou O; Lin CY; Nash P
    Clin Exp Rheumatol; 2019; 37(4):566-574. PubMed ID: 30557128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.
    Kemény L; Berggren L; Dossenbach M; Dutronc Y; Paul C
    J Dermatolog Treat; 2019 Feb; 30(1):19-26. PubMed ID: 29726739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    Imafuku S; Torisu-Itakura H; Nishikawa A; Zhao F; Cameron GS;
    J Dermatol; 2017 Nov; 44(11):1285-1290. PubMed ID: 28635026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
    JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
    Gooderham MJ; Elewski B; Augustin M; Iversen L; Torii H; Burge R; See K; Gallo G; Eastman WJ; McKean-Matthews M; Foley P
    J Drugs Dermatol; 2021 Apr; 20(4):394-401. PubMed ID: 33852247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G; Reich A; Steinhoff M; Beselin A; Kent T; Dossenbach M; Berggren L; Henneges C; Luger T
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):621-637. PubMed ID: 30465321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.